Key findings of the ALEX study: Improved therapeutic options for ALK-positive NSCLC

The key findings of the anaplastic lymphoma kinase-positive non-small cell lung cancer (ALEX) study (NCT02075840) has established alectinib as a key treatment compared with crizotinib. In this talk, S... Author: VJHemOnc Added: 05/17/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts